News & Publications
Catch up with the latest updates, news and publications from the Virtuoso team.
Reference Publications
Technology
Lee et al. “Cell-type specific potent Wnt signaling blockade by bispecific antibody” Sci Reports (2018)
ICAM-1
Biu et al. “ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis” J Leuk Bio (2020)
CD38
Van de Donk et al. “Monoclonal antibodies targeting CD38 in hematological malignancies and beyond” Immuno Rev (2016)
Morandi et al. “CD38: a target for immunotherapeutic approach in multiple myeloma” Frontiers in Immunology (2018)
CD47
Feng et al. “Phagocytosis checkpoints as new targets for cancer immunotherapy” Nat Rev Cancer (2019)
Jaili et al. “Macrophage checkpoint blockage: results from initial clinical trials, binding analyses, and CD47-SIRPa structure-function” Antibody Therapeutics (2020)
Posters
VBI-002, a CD47xICAM-1 Bispecific Antibody for the Treatment of Hepatocellular Carcinoma, Melanoma and Non-Small Cell Lung Cancers
AACR • April 14-19, 2023; Orlando, Florida
VBI-003, a CD47xEpCAM Bispecific Antibody as a Potential Treatment for Colorectal and Small Cell Lung Cancers
AACR • April 14-19, 2023; Orlando, Florida
A novel topoisomerase I inhibitor-based anti-ICAM-1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors
AACR • April 14-19, 2023; Orlando, Florida
Multiple Modes of Action of the CD38 x ICAM-1 Bispecific Antibody
AACR • April 8-13, 2022; New Orleans, LA
VBI-002, a CD47 x ICAM-1 Bispecific Antibody Represents a Novel Approach for Treating ICAM-1 Overexpressing Tumors
AACR • April 8-13, 2022; New Orleans, LA
CD47 x EpCAM Bispecific Antibody Represents a Novel Approach for Treating EpCAM Overexpressing Solid Tumor
SITC • November 10-14, 2021; Washington, D.C.
CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphom
ASH • December 11-14, 2021; Atlanta, GA